• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

February 13, 2023

Worse Brain MRI, Neurodevelopmental Outcomes Show No Link to dDNV Genes

Author(s):

Ashley Gallagher, Editor

The association with subgroups of gene variations based on expression or function should be assessed in larger studies, investigators say.

Worse brain magnetic resonance imaging (MRI) and neurodevelopmental outcomes were not associated with de novo variants in genes not previously associated with neurodevelopmental risk (dDNV-NR) overall, according to the results of a study published in JAMA Network Open.

However, the association of neurodevelopmental impairments with subgroups of gene variations based on expression or function should be assessed in larger studies, investigators said.

Investigators wanted to determine whether neurodevelopmental disabilities commonly associated with congenial heart disease (CHD) and dDNV-NRs were associated with neurological outcomes.

The cross-sectional study was conducted between September 2017 and June 2020 in 8 centers in the United States. Investigators included individuals who were aged 8 years or older with CHD and had available exome sequencing data. Individuals with pathogenic gene variants in CHD or neurodevelopment-related genes were excluded. Investigators matched cases and controls for age group, CHD class, and sex.

The main outcomes of the study included neurodevelopmental assessments of academic achievement, adaptive functioning, attention, anxiety, depression, executive function, fine motor skills, intelligence, language, memory, and social cognition. Additionally, investigators included 7 diffusion, functional, and structural brain MRI metrics.

Investigators included 221 individuals in the post-hoc analysis, as well as 219 in the case-control analysis.

Investigators found that cases and controls had similar primary outcomes, including math computation, reading composite, and spelling on the Wide Range Achievement Test, Fourth Edition, and secondary outcomes.

The dDNVs and/or rare putative loss-of-function variants (pLOFs) in chromatin-modifying genes were associated with lower mean verbal comprehension index scores at 91.4 for cases and 103.4 for controls; the Social Responsiveness Scale, Second Edition, scores at 57.3 and 49.4; and Wechsler Adult Intelligence Scale, Fourth Edition, working memory scores at 73.8 and 97.2, respectively.

Additionally, investigators determined that they were linked with higher likelihood of autism spectrum disorder at 28.6% compared with 5.2%.

The dDNVs and/or pLOFs in constrained genes were associated with lower mean scores on the Wide Range Assessment of Memory and Learning, Second Edition, for immediate story memory at 9.7 for cases and 10.7 for controls and immediate picture memory at 7.8 and 9, respectively.

Adults with dDNVs and/or pLOFs in genes with a high level of brain expression had greater Conners adult attention-deficit hyperactivity disorder rating scale scores, with a mean of 55.5 for cases and 46.6 for controls.

Limitations of the study included the sample size, which investigators said increases the likelihood of a type 2 error.

Additionally, investigators noted that the genes could be constrained because of essential functions, which were unrelated to the structure of the brain and heart.

Furthermore, investigators said that survivor bias in the study could have reduced their ability to identify genes that were associated with earlier death in adults and older children in the study.

They concluded that the presence of dDNV-NR was not associated with adverse neurodevelopmental performance or brain MRI findings among individuals with CHD.

Reference

Morton SU, Norris-Brilliant A, Cunningham S, King E, et al. Association of potentially damaging de novo gene variants with neurologic outcomes in congenital heart disease. JAMA Netw Open. 2023;6(1):e2253191. doi:10.1001/jamanetworkopen.2022.53191

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Advertisement
Red blood cells | Image Credit: © fotogurmespb - stock.adobe.com
May 15th 2025

Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Microscopic cellular structure of chronic lymphocytic leukemia | Image Credit: ©AI Photo Stock - stock.adobe.com
May 15th 2025

Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Human brain digital illustration. Electrical activity, flashes and lightning on a blue background - Image credit: Siarhei | stock.adobe.com
May 15th 2025

FDA Grants Orphan Drug Designation to Oligonucleotide Therapeutic for Spinocerebellar Ataxia

Kennedy Ferruggia, Assistant Editor
Psilocybin -- Image credit: TaylerDerden | stock.adobe.com
May 15th 2025

The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder

Craig Kimble, PharmD, MBA, MS, BCACP, TTS Alberto Coustasse, DrPH, MD, MBA, MPH
Related Content
Advertisement
Red blood cells | Image Credit: © fotogurmespb - stock.adobe.com
May 15th 2025

Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Microscopic cellular structure of chronic lymphocytic leukemia | Image Credit: ©AI Photo Stock - stock.adobe.com
May 15th 2025

Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Human brain digital illustration. Electrical activity, flashes and lightning on a blue background - Image credit: Siarhei | stock.adobe.com
May 15th 2025

FDA Grants Orphan Drug Designation to Oligonucleotide Therapeutic for Spinocerebellar Ataxia

Kennedy Ferruggia, Assistant Editor
Psilocybin -- Image credit: TaylerDerden | stock.adobe.com
May 15th 2025

The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder

Craig Kimble, PharmD, MBA, MS, BCACP, TTS Alberto Coustasse, DrPH, MD, MBA, MPH
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.